Compare Heron Therapeutics Inc (HRTX) vs Lumen Technologies Inc (LUMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Lumen Technologies Inc — how do they compare? Heron Therapeutics Inc trades at $0.41 (market cap $68.01M), while Lumen Technologies Inc trades at $5.28 (market cap $5.73B). The key difference: Lumen Technologies Inc is far larger — about 84.3× Heron Therapeutics Inc's market cap, and Heron Therapeutics Inc is trading nearer its 52-week high, Lumen Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Lumen Technologies Inc for 40 Days on average.
| HRTX | LUMN | |
|---|---|---|
Market Cap | $68.01M | $5.73B |
Volume | 1,891,941 | 17,079,799 |
Sector | Health | Media |
52-Week High | $1.49 | $11.83 |
52-Week Low | $0.27 | $5.28 |
Typical Hold Time | 35 Days | 40 Days |
Enterprise Value | $174.75M | $17.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3582, down 8.15% today, with a bullish technical signal from moving averages but mixed earnings. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates, continuing a trend of net losses. Analyst sentiment remains strongly positive with 89% buy ratings, though Zacks issued a Strong Sell rating in July 2026.
The outlook hinges on revenue stabilization and path to profitability. Investment opportunity lies in analyst optimism and product sales growth, but risks include persistent losses, high valuation multiples, and competitive pressures in the biotechnology sector.
Lumen Technologies (LUMN) trades at $5.56, down 5.92% with bearish technical signals. The company reported mixed Q2 2026 results, beating EPS estimates but showing negative profitability metrics. Recent strategic moves include transferring to Nasdaq and launching Intelligent Internet services targeting AI-driven enterprise networking. Revenue declined to $12.4B in 2025 with a net loss of $1.74B, though operating cash flow remains strong at $4.74B. Analyst sentiment is cautious with 61% hold ratings.
LUMN presents a high-risk turnaround opportunity with potential from AI networking growth but faces significant challenges including $17.49B debt load, declining legacy revenue, and negative ROE. The stock's deep value (P/S 0.47) attracts speculative interest, but execution risks and competitive pressures warrant caution. Near-term catalysts include Q3 earnings and Nasdaq listing transition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →
